Impact of Endoscopic Sleeve Gastroplasty in Non-alcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide. Endoscopic sleeve gastroplasty (ESG) has proven to be feasible, safe, and effective in the management of obesity. We performed the first systematic review and meta-analysis evaluating NAFLD and other metabolic parameters 12 months post-ESG. Four observational studies with a total of 175 patients were included. The results showed a significant (p < 0.05) reduction of 4.85 in hepatic steatosis index (95% CI − 6.02, − 3.67), 0.5 in NAFLD fibrosis score (95% CI − 0.80, − 0.19), 6.32 U/l in ALT (95% CI − 9.52, − 3.11), 17.28% in TWL (95% CI − 18.24, − 16.31), 6.31 kg/$ m^{2} $ in BMI (95% CI − 8.11, − 4.52), 47.97% in EWL (95% CI − 49.10, − 46.84), and 0.51% in HbA1c (95% CI − 0.90, − 0.12). ESG improves liver parameters, provides weight loss, and reduces HbA1c levels in patients suffering from NAFLD. Graphical Abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Obesity surgery - 33(2023), 9 vom: 04. Aug., Seite 2917-2926 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nunes, Beanie Conceição Medeiros [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Bariatric |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11695-023-06747-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR052775429 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR052775429 | ||
| 003 | DE-627 | ||
| 005 | 20230818064721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230818s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11695-023-06747-4 |2 doi | |
| 035 | |a (DE-627)SPR052775429 | ||
| 035 | |a (SPR)s11695-023-06747-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nunes, Beanie Conceição Medeiros |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Endoscopic Sleeve Gastroplasty in Non-alcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide. Endoscopic sleeve gastroplasty (ESG) has proven to be feasible, safe, and effective in the management of obesity. We performed the first systematic review and meta-analysis evaluating NAFLD and other metabolic parameters 12 months post-ESG. Four observational studies with a total of 175 patients were included. The results showed a significant (p < 0.05) reduction of 4.85 in hepatic steatosis index (95% CI − 6.02, − 3.67), 0.5 in NAFLD fibrosis score (95% CI − 0.80, − 0.19), 6.32 U/l in ALT (95% CI − 9.52, − 3.11), 17.28% in TWL (95% CI − 18.24, − 16.31), 6.31 kg/$ m^{2} $ in BMI (95% CI − 8.11, − 4.52), 47.97% in EWL (95% CI − 49.10, − 46.84), and 0.51% in HbA1c (95% CI − 0.90, − 0.12). ESG improves liver parameters, provides weight loss, and reduces HbA1c levels in patients suffering from NAFLD. Graphical Abstract | ||
| 650 | 4 | |a Endoscopic sleeve gastroplasty |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a ESG |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a NAFLD |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Obesity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Fatty liver disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Bariatric |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a de Moura, Diogo Turiani Hourneaux |4 aut | |
| 700 | 1 | |a Kum, Angelo So Taa |4 aut | |
| 700 | 1 | |a de Oliveira, Guilherme Henrique Peixoto |4 aut | |
| 700 | 1 | |a Hirsch, Bruno Salomão |4 aut | |
| 700 | 1 | |a Ribeiro, Igor Braga |0 (orcid)0000-0003-1844-8973 |4 aut | |
| 700 | 1 | |a Gomes, Igor Logetto Caetité |4 aut | |
| 700 | 1 | |a de Oliveira, Claudia Pinto Marques |4 aut | |
| 700 | 1 | |a Mahmood, Sultan |4 aut | |
| 700 | 1 | |a Bernardo, Wanderley Marques |4 aut | |
| 700 | 1 | |a de Moura, Eduardo Guimarães Hourneaux |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Obesity surgery |d New York, NY : Springer, 1991 |g 33(2023), 9 vom: 04. Aug., Seite 2917-2926 |w (DE-627)SPR021779120 |w (DE-600)2087903-9 |x 1708-0428 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:9 |g day:04 |g month:08 |g pages:2917-2926 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11695-023-06747-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 9 |b 04 |c 08 |h 2917-2926 | ||